MedPath

Mundipharma (China) Pharmaceutical Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

18

Active:0
Completed:15

Trial Phases

3 Phases

Phase 1:8
Phase 2:1
Phase 3:9

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials

Phase 3
9 (50.0%)
Phase 1
8 (44.4%)
Phase 2
1 (5.6%)

Buprenorphine Transdermal Patches Pharmacokinetic Study

Phase 1
Conditions
Chronic Pain
Interventions
First Posted Date
2019-06-05
Last Posted Date
2019-06-05
Lead Sponsor
Mundipharma (China) Pharmaceutical Co. Ltd
Target Recruit Count
45
Registration Number
NCT03975010
Locations
🇨🇳

The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China

A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain

First Posted Date
2019-05-30
Last Posted Date
2019-06-11
Lead Sponsor
Mundipharma (China) Pharmaceutical Co. Ltd
Target Recruit Count
194
Registration Number
NCT03967327
Locations
🇨🇳

The 81st hospital of the people's liberation army, Nanjing, China

OTR Tablet 10 mg Fasted-state Bioequivalence Study

Phase 1
Completed
Conditions
Chronic Pain
Interventions
First Posted Date
2018-01-18
Last Posted Date
2020-01-31
Lead Sponsor
Mundipharma (China) Pharmaceutical Co. Ltd
Target Recruit Count
24
Registration Number
NCT03403504
Locations
🇨🇳

The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China

OTR Tablet 40 mg Fasted-state Bioequivalence Study

Phase 1
Completed
Conditions
Chronic Pain
Interventions
First Posted Date
2018-01-12
Last Posted Date
2020-01-31
Lead Sponsor
Mundipharma (China) Pharmaceutical Co. Ltd
Target Recruit Count
38
Registration Number
NCT03398278
Locations
🇨🇳

West Hospital, Sichuan University, Chengdu, Sichuan, China

OTR Tablet 40 mg Fed-state Bioequivalence Study

Phase 1
Completed
Conditions
Chronic Pain
Interventions
First Posted Date
2018-01-12
Last Posted Date
2019-11-15
Lead Sponsor
Mundipharma (China) Pharmaceutical Co. Ltd
Target Recruit Count
42
Registration Number
NCT03398330
Locations
🇨🇳

Xiangya Hospital of Central South University, Changsha, Hunan, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.